

CSD/SE/BM-NOTICE/2026-27
May 6, 2026

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: 543064

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Intimation of Board Meeting of the Company

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby intimate that a Meeting of the Board of Directors of the Company will be held on Tuesday, May 12, 2026, *inter alia*, to consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company, for the quarter and financial year ended March 31, 2026.

In continuation to our letter dated March 27, 2026 regarding intimation of Closure of Trading Window for dealing in the shares of the Company for Designated Persons and their immediate relatives, the Trading Window shall remain closed until May 14, 2026.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)

Sisir K. Mishra
Company Secretary & Compliance Officer

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

